ClinicalTrials.gg
RecruitingNCT05711667Updated Oct 6, 2026

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

A Phase 3 interventional study of Biospecimen Collection and Letermovir in Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by Children's Oncology Group. Recruiting at 33 sites in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Children's Oncology Group · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 6, 2026Site recruiting status changedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
142nd of 660
105 · median 40
Started
2024
with 30 others
Phase 3
38 of 823
8 open now
Primary completion
2029-06
later than 217 of 274 live
Registered
696th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 142nd largest by planned enrollment of the 660 interventional ones that give a count, is one of 31 that started in 2024, is one of 38 in phase 3, reaches primary completion later than 217 of the 274 other live ones, and was the 696th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for hematopoietic cell transplant (HCT) reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of letermovir prophylaxis in the prevention of clinically significant CMV infection through Week 14 (\~100 days) post-transplant in children and adolescents receiving allogeneic hematopoietic cell transplant (allo-HCT).

SECONDARY OBJECTIVE:

I. To evaluate the efficacy of letermovir prophylaxis as assessed by CMV-free survival through 24 weeks (\~6 months) post-transplant in pediatric patients.

EXPLORATORY OBJECTIVES:

I. To evaluate the incidence of clinically significant CMV infection through 24 and 52 weeks post-transplant in patients who receive letermovir prophylaxis.

II. To evaluate overall survival post-transplant in patients who receive letermovir prophylaxis.

III. To evaluate time to engraftment and describe the cumulative incidence of non-engraftment among patients who receive letermovir.

IV. To examine the following clinically significant adverse events among patients exposed to letermovir: the total duration of neutropenia through week 14 (\~100 days) post-transplant, the cumulative incidence of acute kidney injury and chronic kidney disease by 52 weeks post-transplant, and total inpatient hospital days by 14 weeks (\~100 days) and 52 weeks post-transplant.

V. Describe patterns of anti-viral resistance at the onset of CMV DNAemia after allo-HCT among patients who receive letermovir prophylaxis.

VI. To describe immune reconstitution and CMV-specific immunity among patients who receive letermovir prophylaxis.

OUTLINE: Enrolled patients will be added to the single arm of the study and receive letermovir prophylaxis.

ARM A: Patients receive letermovir orally (PO) or intravenously (IV) over 60 minutes once daily (QD) starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV polymerase chain reaction (PCR) analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.

ARM B (CLOSED TO ACCRUAL 09/29/2025): Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.

03

Conditions studied

  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 2 years and \< 18 years at the time of enrollment
  • Weight must be >= 6 kg at the time of enrollment
  • Planned HCT (bone marrow, peripheral blood stem cell, or cord blood transplant)
  • Patient must be CMV sero-positive (i.e., recipient CMV immunoglobulin G positive)

    • Note: If a patient has hypogammaglobulinemia but has previously been documented as CMV sero-positive, that is acceptable for study inclusion. For all patients already confirmed to be CMV IgG seropositive, repeat testing is not required within 7 days prior to enrollment. However, the laboratory data determining eligibility must be available in the patient's medical/research record for verification
  • Patient is eligible for entry only if it is feasible for plasma CMV PCR testing to be sent and resulted within the protocol mandated time period

    • Reminder: To limit the likelihood of positive plasma CMV PCR post-enrollment and prior to start of study treatment period, it is recommended that patient enrollment proceed after patients start their transplant preparative regimen
  • Patient must have a performance status corresponding to Lansky/ scores > 50

    • Note: Use Lansky for patients =\< 16 years of age and Karnofsky for patients > 16 years of age. For further reference, see performance status scales scoring under the standard sections for protocols among protocol reference materials provided on the Children's Oncology Group (COG) member website: https://members.childrensoncologygroup.org/prot/reference_materials.asp
  • Estimated > 10 mL/min/1.73 m\^2 and not receiving dialysis
  • Direct =\< 2 mg/dL and serum glutamate-pyruvate transaminase (SPGT) ( [ALT]) =\<10 x (ULN) for age

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L

Exclusion criteria

Exclusion Criteria:

  • Expected inability to tolerate oral formulation of letermovir
  • to letermovir or any component of the formulation
  • History of CMV end organ disease within 6 months (180 days) prior to enrollment

    • Note: CMV end organ disease based on proposed definitions by Ljungman et al. and inclusive of proven, probable or possible disease
  • Receipt of prior HCT within one year of study enrollment
  • Planned prophylactic administration of other anti-CMV medications or cellular products during the study, including:

    • High dose acyclovir (defined as doses >= 1500 mg/m\^2 IV or >= 3200 mg oral (patients >= 40 kg) or >= 2400 mg/m\^2 (patients \< 40 kg) per day)
    • High dose valacyclovir (defined as doses >= 3000 mg/day in patients > 20 kg)
    • Foscarnet
    • Ganciclovir
    • Valganciclovir
    • CMV-directed cytotoxic T lymphocytes
  • Planned receipt of the following medications during the study treatment period; contraindicated medications must be discontinued at least 14 days prior to Day +1

    • Contraindicated medications for all patients:

      • Pimozide
      • Ergot alkaloids
    • Contraindicated medications for patients planned to receive cyclosporine:

      • Bosentan
      • Pitavastatin
      • Simvastatin
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted in certain animal reproduction studies with letermovir. A pregnancy test is required for female patients of
  • Lactating females who plan to breastfeed their infants
  • Sexually active female patients of who have not agreed to use an effective method for the duration of their letermovir treatment and through at least 4 weeks after the last dose of letermovir.

    • Note: No contraception measures are needed specifically during letermovir treatment for male trial participants who have pregnant or non-pregnant female partner(s) of reproductive potential. Contraception measures may be required for other aspects of the HCT procedure.
  • All patients and/or their parents or legal guardians must sign a written
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    ARM A (Letermovir prophylaxis)

    Patients receive letermovir PO or IV over 60 minutes QD starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.

    Procedure: Biospecimen Collection · Drug: Letermovir

  • Active comparator
    Arm B (No prophylaxis)

    Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52. (CLOSED TO ACCURAL 09/29/2025)

    Procedure: Biospecimen Collection

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given PO or IV

    Also known as: 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis

06

What researchers measure

Primary outcomes

  1. Clinically significant cytomegalovirus (CMV) infection

    Clinically significant CMV is defined as the first of (1) initiation of anti-CMV preemptive therapy for documented CMV DNAemia or (2) onset of CMV end-organ disease. Will estimate the 14 week cause-specific cumulative incidence of clinically significant CMV under the non-parametric, Aalen-Johansen estimator of the cumulative incidence function. Will estimate the 95% upper 1-sided confidence limit of the cause-specific cumulative incidence at 100-days post-hematopoietic cell transplantation using a bias-corrected and accelerated bootstrap-based confidence interval.

    Time frame: Up to week 14 post-transplant

Secondary outcomes

  1. Detection of CMV DNAemia

    Will estimate the cumulative incidence of CMV DNAemia at 24-weeks post-transplant by study arm and will report the corresponding 95% confidence intervals.

    Time frame: Up to week 24 post-transplant

  2. CMV-free survival

    Will estimate the cumulative incidence of the occurrence of CMV DNAemia or death by week 24 post-transplant by study arm and will report the corresponding 95% confidence intervals.

    Time frame: Up to 24 weeks post-transplant

Other outcomes

  1. Clinically significant CMV infection in early follow up

    Clinically significant CMV is defined as the first of (1) initiation of anti-CMV preemptive therapy for documented CMV DNAemia or (2) onset of CMV end-organ disease. Will estimate the cumulative incidence of clinically significant CMV at 24-weeks post-transplant and will report the corresponding 95% confidence interval.

    Time frame: Up to 24 weeks post-transplant

  2. Clinically significant CMV infection in late follow up

    Clinically significant CMV is defined as the first of (1) initiation of anti-CMV preemptive therapy for documented CMV DNAemia or (2) onset of CMV end-organ disease. Will estimate the cumulative incidence of clinically significant CMV at 52-weeks post-transplant and will report the corresponding 95% confidence interval.

    Time frame: Up to 52 weeks post-transplant

  3. Overall survival (OS) in early follow up

    The Kaplan-Meier method will be used to estimate the 24-week OS probability, as defined by time from transplant until death. The corresponding 95% confidence interval will be reported.

    Time frame: Up to 24 weeks post-transplant

  4. Overall survival (OS) in late follow up

    The Kaplan-Meier method will be used to estimate the 52-week OS probability, as defined by time from transplant until death. The corresponding 95% confidence interval will be reported.

    Time frame: Up to 52 weeks post-transplant

  5. Neutrophil engraftment

    Engraftment is defined as the first three days of neutrophil count values above 500 cells/μL. Will estimate the cumulative incidence of neutrophil engraftment at 60-days post-transplant and will report the corresponding 95% confidence interval.

    Time frame: Up to 60 days post-transplant

  6. Incidence of neutropenia

    Neutropenia will be defined as an absolute neutrophil count \< 500 cells/uL. Will estimate the median number of weeks of neutropenia post-transplant.

    Time frame: Up to 14 weeks post-transplant

  7. Incidence of acute kidney injury

    Acute kidney injury will be defined as grade 3 or higher creatinine elevation using the common terminology criteria for adverse events (CTCAE) version (v)5 definitions. Will estimate the cumulative incidence of acute kidney injury at 52-weeks post-transplant and will report the corresponding 95% confidence interval.

    Time frame: Up to 52 weeks post-transplant

  8. Incidence of chronic kidney disease

    Chronic kidney disease will be defined as grade 2 or higher using the CTCAE v5 definitions. Will estimate the cumulative incidence of chronic kidney disease at 52-weeks post-transplant and will report the corresponding 95% confidence interval.

    Time frame: Up to 52 weeks post-transplant

  9. Number of inpatient hospital days

    Will report the median number of inpatient hospital days post-transplant.

    Time frame: Up to 14 weeks post-transplant

  10. Number of inpatient hospital days

    Will report the median number of inpatient hospital days post-transplant.

    Time frame: Up to one-year post-transplant

  11. Incidence of resistance to antiviral medications

    Will estimate the cumulative incidence of resistance to antiviral medications among the patients who develop clinically significant CMV infection. This analysis will be restricted to patients with viral loads \> 1000 IU/mL.

    Time frame: Up to 14 weeks post-transplant

  12. CD4+ lymphocyte count

    Will report the median CD4+ lymphocyte count.

    Time frame: At 14, 24, and 52 weeks post-transplant

  13. CD8+ lymphocyte count

    Will report the median CD8+ lymphocyte count.

    Time frame: At 14, 24, and 52 weeks post-transplant

07

Study locations

32 of 33 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2029, 59 months after the start.

Of 41 phase 3 interventional studies under Hematologic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 81. This study's planned 59 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 3, 2023
StartActual
Jul 11, 2024
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. VCU Massey Comprehensive Cancer Center is now Recruiting
Show 4 added (4 United States)
  • New York Medical College · Valhalla, United States
  • Nationwide Children's Hospital · Columbus, United States
  • Penn State Children's Hospital · Hershey, United States
  • Cook Children's Medical Center · Fort Worth, United States
Oct 6, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionClinically significant cytomegalovirus (CMV) infection: how it is measured was reworded
Oct 6, 2026
Secondary outcomes
1 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameDetection of CMV DNAemiaUp to week 14 post-transplant → Up to week 24 post-transplant
  • DescriptionDetection of CMV DNAemia: how it is measured was reworded
  • Descriptionother outcomeIncidence of acute kidney injury: how it is measured was reworded
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    4 sites added. VCU Massey Comprehensive Cancer Center is now Recruiting
    Show 4 added (4 United States)
    • New York Medical College · Valhalla, United States
    • Nationwide Children's Hospital · Columbus, United States
    • Penn State Children's Hospital · Hershey, United States
    • Cook Children's Medical Center · Fort Worth, United States
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionClinically significant cytomegalovirus (CMV) infection: how it is measured was reworded
    Secondary outcomes 1 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameDetection of CMV DNAemiaUp to week 14 post-transplant → Up to week 24 post-transplant
    • DescriptionDetection of CMV DNAemia: how it is measured was reworded
    • Descriptionother outcomeIncidence of acute kidney injury: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05711667
Responsible party
Sponsor
First posted
Feb 3, 2023
Start date
Jul 11, 2024
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Caitlin W Elgarten
principal investigator · Children's Oncology Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion